Conclusions: The present study shows excellent safety and efficacy outcomes associated with septal reduction strategies in a high-flow HCM institution with moderate procedural volume. Perioperative mortality was comparable to that of major surgical centres. SM showed better long-term results than ASA in the present study, although this finding must be weighed against a more adverse baseline clinical profile of the ASA population.
P2316Outcome of septal reduction therapies for obstructive hypertrophic cardiomyopathy in a high-flow referral centre with moderate volume procedural programmes / Fumagalli, C., Cavigli, L., Rossi, A., Arretini, A., Targetti, M., Passantino, S., Girolami, F., Maurizi, N., Marchionni, N., Antoniucci, D., Cecchi, F., Yacoub, M.H., Stefano, P., Olivotto, I.. - In: EUROPEAN HEART JOURNAL. - ISSN 0195-668X. - ELETTRONICO. - 38:(2017), pp. 462-462. [10.1093/eurheartj/ehx502.P2316]
P2316Outcome of septal reduction therapies for obstructive hypertrophic cardiomyopathy in a high-flow referral centre with moderate volume procedural programmes
Fumagalli, C.;Arretini, A.;Targetti, M.;Passantino, S.;Marchionni, N.;Yacoub, M. H.;Stefano, P.;Olivotto, I.
2017
Abstract
Conclusions: The present study shows excellent safety and efficacy outcomes associated with septal reduction strategies in a high-flow HCM institution with moderate procedural volume. Perioperative mortality was comparable to that of major surgical centres. SM showed better long-term results than ASA in the present study, although this finding must be weighed against a more adverse baseline clinical profile of the ASA population.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
